SCHEMBL4931270

SCHEMBL4931270

Nc1ccc(-c2cc(C(=O)N3CCC(F)(F)CC3)nn2-c2cnccn2)nc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 9/20 0.40
ALDH1A1 P00352 2/20 0.39
CHRNA7 P36544 1/20 0.37
CYP2D6 P10635 5/20 0.37
CYP2C19 P33261 2/20 0.37
USP2 O75604 4/20 0.37
HSD17B10 Q99714 3/20 0.37
CYP2C9 P11712 2/20 0.37
CASP1 P29466 1/20 0.37
HIF1A Q16665 2/20 0.36
CYP1A2 P05177 5/20 0.36
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP7 Q9UHL4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4934939 0.89 CYP3A4 (0.40) CYP3A4ALDH1A1CYP2D6CYP2C19USP2
SCHEMBL4931713 0.86 CHRNA7 (0.40) CYP3A4CHRNA7CYP2C19USP2CYP2C9
SCHEMBL4932361 0.81 CYP1A2 (0.38) CYP3A4ALDH1A1CYP2D6CYP2C19CYP2C9
SCHEMBL4933069 0.77 HTR1A (0.42) CYP3A4ALDH1A1CYP2D6CYP2C19HSD17B10
SCHEMBL4931192 0.76 MGLL (0.45) CYP3A4CHRNA7CYP2C19USP2HSD17B10
SCHEMBL4927670 0.75 CHRNA7 (0.41) CYP3A4ALDH1A1CHRNA7CYP2C19USP2
SCHEMBL5272992 0.75 CYP2C9 (0.39) CYP3A4ALDH1A1CYP2D6CYP2C19USP2
SCHEMBL4931848 0.75 CHRNA7 (0.46) CYP3A4CHRNA7CYP2C19USP2CYP2C9
SCHEMBL4931684 0.75 KDM1A (0.43) CYP3A4CHRNA7CYP2C19USP2CYP2C9
SCHEMBL4933045 0.75 CHRNA7 (0.40) CYP3A4CHRNA7CYP2D6CYP2C19USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US disclosed
CN-1980912-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2007-06-13 CN disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 CYP3A4 65/4885ALDH1A1 248/4885CHRNA7 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.